Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: toccodolce who wrote (9085)	3/23/2002 12:20:23 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

Hi Tom, Boy there are a lot of late nighters on this thread. Both Mark and DI7026 talked about this on the other DMX board. Here is a clip of DI's comments: ...the drugs for HIV are NNRTI and PI, both are antivirals, one for the reverse transcriptase the other for the protease enzyme. They were discovered via rational drug design approach and they are intended to be used for resistant HIV arisen as a result of the current cocktail treatment. WF10 on the other hand, deals with AIDS and HCV by modulating the immune system, and it is not an antiviral. So to answer your question, WF10 is distinctly different than the other 2 drugs and it is intended to be used in conjuction with antiviral drugs. I had said that I felt DMX would begin moving back up last week after Monday. This was based on an estimation of when the placement would end, combined with the DMI at 12 and slow stochastic in the teens, as well as my personal estimation that the new FDA profile would keep the bottom higher (using a 6 month daily chart). The flat SS over the last 6 days below 20 is unusual for DMX and the daily, weekly, and monthly charts all have a DMI in the teens. I was wrong on the turn last week. I'm more sure though that a trend is coming very soon. None of this matters to me because I've got every share of DMX I'm probably ever going to own and as I've clearly stated both the trading ranges and the exact timing couldn't be less relevant during this period. It has all evolved to a single point around the central issue of Pennsaid. FDA. Yes or no. I had a long talk with a DMX investor who's never read a bulletin board. We both agreed that the biggest risk wasn't getting the FDA approval which we each rated as over 80% probable now - it was that we each had a "feeling" about the CEO. That she had what it takes. Its been quite a journey watching all the vitriol when the truth is she's one of the bigger reasons I invested and held. The risk we are all now taking is laughable compared to the huge risk we were taking years ago. I'm not starting to anticipate big news until May. With the exception that I believe we will have a WF10 update and european news by then. And either way this journey gets resolved in 2002 for me. Out and on to something else, or watch Johnson & Johnson enter the US arthritis market with a different approach to NSAID's. Read a book. Wolf